Latest Market News

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Marquee Resources has identified significant gold anomalies across its 106 km² Yindi Gold Project in Western Australia, backed by a thorough review of historical drilling data. The company plans targeted drilling to validate promising intercepts near major gold operations.

Stavely Minerals advances exploration in the Stavely Volcanic Belt with fresh drilling at key gold prospects and a strong copper-gold-silver resource base, signaling potential growth in energy metals.

archTIS Limited has successfully raised $7.5 million through a share placement, aiming to fuel its international growth strategy focused on U.S. market expansion, strategic partnerships, and product development.

ClearVue Technologies announces key leadership changes with COO Douglas Hunt stepping in as interim CEO, alongside two new board appointments, signaling a strategic push to accelerate growth and innovation.

Kaiser Reef Limited has reported its strongest quarterly gold production to date, driven by the successful acquisition and integration of the Henty Gold Mine in Tasmania.

Amaero has successfully qualified its C103 and Ti64 metal powders through a collaboration with Auburn University’s NCAME, meeting Velo3D’s standards and paving the way for initial commercial shipments in FY2026.

DY6 Metals has addressed an ASX price query by confirming confidential negotiations for acquiring additional mining licenses in Cameroon, explaining recent share price movements and ensuring compliance with continuous disclosure rules.

Platinum Asset Management and L1 Capital have announced a strategic merger to create a diversified investment platform with $16.5 billion in assets under management, promising significant cost synergies and earnings accretion for shareholders.

Platinum Asset Management and L1 Capital have agreed to merge, creating a combined entity managing approximately A$16.5 billion in assets. The deal promises strategic diversification, cost synergies, and significant earnings accretion for shareholders.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.

Ryder Capital has halted its Dividend Reinvestment Plan, opting to pay shareholders cash dividends instead. The move raises questions about the company’s strategic direction and shareholder returns.